Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

Broadly speaking, the loss of co-formulation patent extension rights undercuts HALO's value to possible partners who saw that protection advantage as a motivation to pursue subcu products. Assuming this protection is no longer a workable model (this is not totally clear yet, so I'm speaking worst case scenario) any future partnerships will solely be based on consumer preference and convenience, a more slender reed to be sure.
This ruling may even affect the pending "three new deals" mentioned by Helen in her recent comments. If they are still able to get thiese deals over the goal line, then that'll be a good sign, but delays in this regard will be telling.